Warning: The NCBI web site requires JavaScript to function. more...
Cost-effectiveness of smoking cessation to prevent age-related macular degeneration.
Hurley SF, Matthews JP, Guymer RH.
Cost Eff Resour Alloc. 2008 Sep 11;6:18.
Related citations
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration.
Cost Eff Resour Alloc. 2008 Jun 24;6:12.
Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment.
Kaper J, Wagena EJ, van Schayck CP, Severens JL.
Pharmacoeconomics. 2006;24(5):453-64.
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP.
J Manag Care Pharm. 2010 Apr;16(3):217-30. Review.
'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.
Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.
Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.
Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.
Pharmacoeconomics. 2007;25(10):863-79.
A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.
Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Earnshaw SR, Moride Y, Rochon S.
Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.
Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
Curr Med Res Opin. 2010 Mar;26(3):549-60.
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
Health Technol Assess. 2005 Jun;9(22):1-160. Review.
Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T.
JAMA. 1997 Dec 3;278(21):1759-66.
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.
Clin Drug Investig. 2009;29(10):655-65. doi: 10.2165/11317730-000000000-00000.
A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA.
Scand J Public Health. 2005;33(5):343-52.
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.
Ophthalmology. 2001 Nov;108(11):2051-9.
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Bolin K, Lindgren B, Willers S.
Chest. 2006 Mar;129(3):651-60.
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
Curr Med Res Opin. 2008 Jan;24(1):51-61.
Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.
Igarashi A, Takuma H, Fukuda T, Tsutani K.
Pharmacoeconomics. 2009;27(3):247-61. doi: 10.2165/00019053-200927030-00007.
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
Clin Ther. 2008 Dec;30(12):2436-51.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on